{
    "clinical_study": {
        "@rank": "62172", 
        "arm_group": [
            {
                "arm_group_label": "Ia: MenABCWY+OMV", 
                "arm_group_type": "Experimental", 
                "description": "Investigational"
            }, 
            {
                "arm_group_label": "Ib: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Saline"
            }, 
            {
                "arm_group_label": "IIa: MenABCWY+\u00bcOMV", 
                "arm_group_type": "Experimental", 
                "description": "Investigational"
            }, 
            {
                "arm_group_label": "IIb: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Saline"
            }, 
            {
                "arm_group_label": "IIIa: MenABCWY+OMV", 
                "arm_group_type": "Experimental", 
                "description": "Investigational"
            }, 
            {
                "arm_group_label": "IIIb: MenABCWY+\u00bcOMV", 
                "arm_group_type": "Experimental", 
                "description": "Investigational"
            }, 
            {
                "arm_group_label": "IVa: MenABCWY+OMV", 
                "arm_group_type": "Experimental", 
                "description": "Investigational"
            }, 
            {
                "arm_group_label": "IVb: MenABCWY+\u00bcOMV", 
                "arm_group_type": "Experimental", 
                "description": "Investigational"
            }, 
            {
                "arm_group_label": "IVc: Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Saline"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this extension study is to evaluate the immunogenicity and safety of a\n      booster dose of a MenABCWY vaccine, administered 24 months after completion of the primary\n      vaccination series, in subjects who previously received the same vaccine formulation in\n      study V102_03 (Groups I and II). Antibody persistence at 24 and 36 months after the primary\n      vaccination and 12 months after the booster dose will also be evaluated in these subjects.\n\n      In addition, safety and immunogenicity of two investigational MenABCWY vaccine formulations\n      (either a MenABCWY+ OMV or a MenABCWY+\u00bc OMV) will be assessed in subjects who previously\n      received two doses of MenB vaccine (Group III) or one dose of Menveo vaccine (Group IV).\n      These subjects will be followed for safety and immunogenicity for 12 months after\n      vaccination in study V102_03E1."
        }, 
        "brief_title": "Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Meningococcal Disease", 
        "condition_browse": {
            "mesh_term": "Meningococcal Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and females that received both vaccinations and completed the Study Termination\n             visit in the primary study, V102_03;\n\n          2. Individuals or the individual's parents or legal guardian who have given written\n             consent after the nature of the study has been explained according to local\n             regulatory requirements;\n\n          3. Individuals who have given written assent as required by local regulations after the\n             nature of the study has been explained to them according to local regulatory\n             requirements;\n\n          4. Individuals in good health as determined by the outcome of medical history, physical\n             examination and clinical judgment of the investigator;\n\n          5. Individuals and/or or the individual's parents or legal guardian who can comply with\n             study procedures and are available for follow-up.\n\n        Exclusion Criteria:\n\n          1. History of any meningococcal vaccine administration other than the vaccination\n             administered in the primary study, V102_03;\n\n          2. Current or previous, confirmed or suspected disease caused by N. meningitidis;\n\n          3. Household contact with and/or intimate exposure to an individual with any laboratory\n             confirmed N. meningitidis infection within 60 days of enrollment;\n\n          4. History of severe allergic reactions after previous vaccinations or hypersensitivity\n             to any vaccine component;\n\n          5. All sexually active females that have not used an \"acceptable contraceptive\n             method(s)\" for at least 2 months prior to study entry. Acceptable birth control\n             methods are defined as one or more of the following:\n\n               1. Hormonal contraceptive (such as oral, injection, transdermal patch, implant,\n                  cervical ring)\n\n               2. Barrier (condom with spermicide or diaphragm with spermicide) each and every\n                  time during intercourse Intrauterine device (IUD)\n\n             d. Monogamous relationship with vasectomized partner. Partner must have been\n             vasectomized for at least six months prior to the subject's study entry;\n\n          6. Sexually active females that refuse to use to an \"acceptable contraceptive method\"\n             through to 3 weeks following the study vaccination;\n\n          7. Female subjects with a positive pregnancy test prior to the study vaccine being\n             administered;\n\n          8. Nursing (breastfeeding) mothers;\n\n          9. Individuals with a history of illness or with an ongoing illness that, in the opinion\n             of the investigator, may pose additional risk to the subject if he/she participates\n             in the study;\n\n         10. Any serious, chronic, or progressive disease (e.g., neoplasm, diabetes, cardiac\n             disease, hepatic disease, progressive neurological disease or seizure disorder;\n             autoimmune disease, HIV infection or AIDS, blood dyscrasias, bleeding diathesis,\n             signs of cardiac or renal failure, or severe malnutrition);\n\n         11. Subjects who required chronic administration (defined as more than 14 days) of\n             immunosuppressants or other immune-modifying drugs within six months prior to the\n             study vaccination. (For corticosteroids, this means prednisone, or equivalent,\n             \u226520mg/day. Inhaled and topical steroids are allowed).\n\n         12. Receipt of blood, blood products and/or plasma derivatives, or a parenteral\n             immunoglobulin preparation within the previous 90 days;\n\n         13. Individuals participating in any clinical trial with another investigational product\n             30 days prior to first study visit or intent to participate in another clinical study\n             at any time during the conduct of this study;\n\n         14. Administration or planned administration, of any vaccine not foreseen by the study\n             protocol within 30 days prior study vaccination, and up to 30 days after the\n             vaccination (with the exception of any licensed influenza vaccine which may be\n             administered >14 days preceding or >14 days following the study vaccination);\n\n         15. Individuals who study personnel or immediate family members of study personnel\n             including brother, sister, child, parent, or the spouse.\n\n         16. Individuals who have experienced moderate or severe acute infection and/or fever\n             (defined as temperature >38\u00b0C) within 3 days prior to enrolment.\n\n         17. Who have received systemic antibiotic treatment within 7 days prior to enrolment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "25 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "194", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992536", 
            "org_study_id": "V102_03E1", 
            "secondary_id": "2012-003937-41"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ia: MenABCWY+OMV", 
                    "IIIa: MenABCWY+OMV", 
                    "IVa: MenABCWY+OMV"
                ], 
                "description": "Vaccine contains rMenB (50 \u00b5g per antigen) with 25 \u00b5g of OMV (a \"full\" dose) plus the fully lyophilized MenACWY vaccine", 
                "intervention_name": "MenABCWY+OMV", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "IIa: MenABCWY+\u00bcOMV", 
                    "IIIb: MenABCWY+\u00bcOMV", 
                    "IVb: MenABCWY+\u00bcOMV"
                ], 
                "description": "Vaccine contains rMenB (50 \u00b5g per antigen) with 6.25 \u00b5g OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine", 
                "intervention_name": "MenABCWY+\u00bcOMV", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Ib: Placebo", 
                    "IIb: Placebo", 
                    "IVc: Placebo"
                ], 
                "description": "Saline solution for injection (0.5mL)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Meningococcal", 
            "Booster", 
            "MenABCWY", 
            "Menveo", 
            "Vaccine Adolescents", 
            "Immune Response", 
            "N. Meningitidis"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35205"
                    }, 
                    "name": "Site 23, Alabama Clinical Therapeutics 806 St. Vincent's Drive, Suite 615"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madera", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93637"
                    }, 
                    "name": "Site 24, Madera Family Medical Group 1111 West 4th Street"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paramount", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90723"
                    }, 
                    "name": "Site 25, Center for Clinical Trials LLC 16660 Paramount Blvd, Suite 301"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bardstown", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40004"
                    }, 
                    "name": "Site 28, Kentucky Pediatric/Adult Research 201 South 5th Street"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40291"
                    }, 
                    "name": "Site 21, Bluegrass Clinical Research Inc. 5512 Bardstown Road, Suite 2"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45414"
                    }, 
                    "name": "Site 26, Ohio Pediatric Research Association 7200 Poe Ave, Suite 200"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kettering", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45420"
                    }, 
                    "name": "Site 27, Ohio Pediatric Research Association 1775 Delco Park Drive"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37087"
                    }, 
                    "name": "Site 22, Focus Research Group 201 Signature Place"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ul.Ko\u015bciuszki 41", 
                        "country": "Poland", 
                        "state": "Izabelin", 
                        "zip": "05-080"
                    }, 
                    "name": "Site 15, Specjalistyczna Przychodnia Lekarska Internistyczno-Pediatryczna, Juniperus\" s.c."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ul. Braci Kiemlicz\u00f3w 14", 
                        "country": "Poland", 
                        "state": "Krak\u00f3w", 
                        "zip": "31-223"
                    }, 
                    "name": "Site 13, Hanna Czajka Indywidualna Specjalistyczna Praktyka Lekarska"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ul.Strzelc\u00f3w 15", 
                        "country": "Poland", 
                        "state": "Krak\u00f3w", 
                        "zip": "31-422"
                    }, 
                    "name": "Site 12, NZOZ PRAKTIMED Sp.zo.o"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ul. Ceg\u0142owska 80", 
                        "country": "Poland", 
                        "state": "Warszawa", 
                        "zip": "01-809"
                    }, 
                    "name": "Site 14, Klinika Pediatrii Centrum Medycznego Kszta\u0142cenia Podyplomowego,Szpital Biela\u0144ski"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ul.O.Bujwida 44", 
                        "country": "Poland", 
                        "state": "Wroc\u0142aw", 
                        "zip": "50-354"
                    }, 
                    "name": "Site 11, Katedra i Klinika Pediatrii i Chor\u00f3b Infekcyjnych"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Poland"
            ]
        }, 
        "number_of_arms": "9", 
        "official_title": "Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03", 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Poland: The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of subjects with seroresponse to N. meningitidis serogroups A, C, W and Y", 
                "safety_issue": "No", 
                "time_frame": "30 days following administration of a MenABCWY vaccination or placebo"
            }, 
            {
                "measure": "Percentage of subjects with hSBA titer >=1:5 to N. meningitidis serogroups B strains", 
                "safety_issue": "No", 
                "time_frame": "30 days following administration of a MenABCWY vaccination or placebo"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992536"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of subjects with hSBA titer >=1:8 to N. meningitidis serogroups A, C, W and Y", 
                "safety_issue": "No", 
                "time_frame": "Prior to Vaccination"
            }, 
            {
                "measure": "Percentage of subjects with hSBA titer >=1:5 s to N. meningitidis serogroups B strains", 
                "safety_issue": "No", 
                "time_frame": "Prior to Vaccination"
            }, 
            {
                "measure": "hSBA GMTs against N. meningitidis serogroups A, C, W and Y and strains of serogroup B", 
                "safety_issue": "No", 
                "time_frame": "Prior to Vaccination"
            }, 
            {
                "measure": "Percentage of subjects with hSBA titer >=1:8 and GMTs to N. meningitidis serogroups A, C, W and Y", 
                "safety_issue": "No", 
                "time_frame": "30 days following administration of a MenABCWY vaccination or placebo"
            }, 
            {
                "measure": "Percentage of subjects with four-fold rise and GMTs to N. meningitidis serogroups B strains", 
                "safety_issue": "No", 
                "time_frame": "30 days following administration of a MenABCWY vaccination or placebo"
            }, 
            {
                "measure": "hSBA GMTs against N. meningitidis serogroups A, C, W and Y and strains of serogroup B", 
                "safety_issue": "No", 
                "time_frame": "30 days following administration of a MenABCWY vaccination or placebo"
            }, 
            {
                "measure": "Percentage of subjects with seroresponse and with hSBA titer >=1:8 against N. meningitidis serogroups A, C, W and Y", 
                "safety_issue": "No", 
                "time_frame": "365 days following administration of a MenABCWY vaccination or placebo"
            }, 
            {
                "measure": "Percentage of subjects with hSBA titer >=1:5, and with four-fold rise against N.meningitidis serogroups B strains", 
                "safety_issue": "No", 
                "time_frame": "365 days following administration of a MenABCWY vaccination or placebo"
            }, 
            {
                "measure": "hSBA GMTs", 
                "safety_issue": "No", 
                "time_frame": "365 days following administration of a MenABCWY vaccination or placebo"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}